Internal Medicine, Hematology & Oncology · Farmington Hills, MI
NPI
1548260128
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
7
Medicare group memberships
Hospitals
1
Hospital affiliations
34743 Huntington Court
Farmington Hills, MI, 48331
Phone (248) 794-3759
Groups this clinician bills Medicare through
Medicare paid, 2023
$3,674
51 services
Medicare patients, 2023
40
Average age 76
Drug cost, 2024
$1.4M
399 prescriptions
Company payments, 2025
$39.33
From 2 companies
Procedures and visits billed to Original Medicare, 2023
In 2023, the most common Medicare service billed by Mustafa G Boxwala was code 99214 (office e&m - established), 45 times for 35 patients. In total Mustafa G Boxwala billed 51 services in 3 codes, and Medicare paid $3,674.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-08-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 45 | 35 | $73.71 | $3,317 |
Medicare prescription drug claims, 2024
In 2024, the drug Mustafa G Boxwala prescribed most often to Medicare patients was Dexamethasone, with 34 prescriptions and refills. In total Mustafa G Boxwala wrote 399 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Dexamethasone Generic | 34 | 34 | Under 11 | $265 |
| Anastrozole Generic | 29 | 29 | Under 11 | $1,877 |
| Velcade Bortezomib | 21 | 21 | Under 11 | $23K |
| Acyclovir Generic | 18 | 18 | Under 11 | $772 |
| Ondansetron Odt Ondansetron | 17 | 17 | Under 11 | $5,305 |
| Xgeva Denosumab | 17 | 17 | Under 11 | $58K |
| Zirabev Bevacizumab-Bvzr | 16 | 16 | Under 11 | $111K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 14 | 14 | Under 11 | $107 |
| Tamoxifen Citrate Generic | 14 | 14 | Under 11 | $357 |
| Keytruda Pembrolizumab | 13 | 13 | Under 11 | $258K |
| Sutent Sunitinib Malate | 13 | 13 | Under 11 | $52K |
| M-Natal Plus Pnv,calcium 72/Iron/Folic Acid | 12 | 12 | Under 11 | $59.04 |
| Neulasta Onpro Pegfilgrastim | 12 | 12 | Under 11 | $78K |
| Herceptin Trastuzumab | 11 | 11 | Under 11 | $64K |
| Ziextenzo Pegfilgrastim-Bmez | 11 | 11 | Under 11 | $45K |
Brand drugs: 199 claims; generic drugs: 188 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mustafa G Boxwala $39.33 ($39.33 in general payments such as food, travel and fees) from 2 companies. The largest payer was Ethicon Inc. with $25.6.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.